Elizabeth Holt

iOnctura has appointed Elizabeth Holt as Chief Business Officer

iOnctura has announced the appointment of Elizabeth Holt, former Co-Founder of Aiolos Bio, as its Chief Business Officer.

Holt brings extensive biopharmaceutical experience to the role. In addition to being part of the founding team for Aiolos Bio, which was acquired by GSK in February last year, Holt served as the company’s Vice President of Corporate Strategy and Operations.

She also previously held senior roles at Tier One Bio and Gyroscope Therapeutics, and was an Associate Partner with McKinsey & Company earlier in her career.

Alongside Holt’s appointment, iOnctura has named Mark Velleca, current Chief Executive Officer (CEO) of Black Diamond Therapeutics (BDTX), as Chair of its Board of Directors.

Velleca is also Board Chair of both BDTX and Myeloid Therapeutics, and previously served as CEO of G1 Therapeutics.

Catherine Pickering, CEO and Co-Founder of iOnctura said: “Our team is carefully selected. Mark and Elizabeth have significant healthcare and corporate experience which will be invaluable as we progress our… pipeline through clinical development.”